Vadhan‐Raj 2013.

Study characteristics
Methods	Trial acronym: none reported, registry Identifier of NCI CTRP: NCI‐2011‐01773 Design: randomised, open‐label, parallel‐group trial Median duration of follow‐up: not reported
Participants	Patients aged ≥ 18 years with a diagnosis of advanced stage (unresectable or metastatic) adenocarcinoma of the pancreas planning to initiate systemic chemotherapy within 2 weeks, ECOG performance status 0–2, adequate renal function (creatinine clearance > 50 mL/minute). Mean age: 52 (range 36–77) years overall; 59 (range 36–75) years in dalteparin group; 64 (range 38–77) years in control group Gender, n (%) males: 41 (54.7%) males overall; 20 (52.6%) in dalteparin group; 21 (56.8%) in control group Metastatic disease: not reported Previous VTE: not reported
Interventions	Intervention: LMWH, dalteparin (5000 IU SC, once daily) for 16 weeks during chemotherapy Control: chemotherapy alone
Outcomes	Primary outcome: venous thromboembolic events during 16 weeks of treatment Other outcomes mentioned in the abstract: adverse events, clinically significant bleeding, overall survival
Notes	Funding: not reported; however, Eisai Inc. is listed as collaborator at ClinicalTrials.gov Disclosure of potential conflicts of interest: not reported Publication format: published conference abstract Baseline characteristics and overall VTE outcome data available at clinicaltrials.gov/ct2/show/results/NCT00966277. The trial database was used as source for data extraction.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "were randomized 1:1 to dalteparin vs control arms." Comment: method of sequence generation not reported.
Allocation concealment (selection bias)	Unclear risk	Quote: "were randomized 1:1 to dalteparin vs control arms." Comment: method of allocation concealment not reported.
Blinding (performance bias and detection bias) All outcomes	High risk	Comment: open‐label study. It is not reported in the abstract if outcome assessors were blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "All 75 patients were evaluable for response in an intent‐to‐treat analysis." Comment: all randomised participants were included in the analysis.
Selective reporting (reporting bias)	Unclear risk	Comment: study not published as full report yet. The conference abstract did not address all planned outcomes in sufficient detail.